These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15081143)

  • 1. Use of an impinging jet for dispersion of dry powder inhalation aerosols.
    Wang Z; Lange CF; Finlay WH
    Int J Pharm; 2004 May; 275(1-2):123-31. PubMed ID: 15081143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
    Schiavone H; Palakodaty S; Clark A; York P; Tzannis ST
    Int J Pharm; 2004 Aug; 281(1-2):55-66. PubMed ID: 15288343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of mixing of fine carrier particles on dry powder inhalation property of salbutamol sulfate (SS)].
    Iida K; Leuenberger H; Fueg LM; Müller-Walz R; Okamoto H; Danjo K
    Yakugaku Zasshi; 2000 Jan; 120(1):113-9. PubMed ID: 10655787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The contribution of different formulation components on the aerosol charge in carrier-based dry powder inhaler systems.
    Hoe S; Traini D; Chan HK; Young PM
    Pharm Res; 2010 Jul; 27(7):1325-36. PubMed ID: 20354768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics.
    Hickey AJ; Mansour HM; Telko MJ; Xu Z; Smyth HD; Mulder T; McLean R; Langridge J; Papadopoulos D
    J Pharm Sci; 2007 May; 96(5):1302-19. PubMed ID: 17455364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Particle engineering using sonocrystallization: salbutamol sulphate for pulmonary delivery.
    Dhumal RS; Biradar SV; Paradkar AR; York P
    Int J Pharm; 2009 Feb; 368(1-2):129-37. PubMed ID: 18996462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
    Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
    Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet size.
    Coates MS; Chan HK; Fletcher DF; Raper JA
    J Pharm Sci; 2006 Jun; 95(6):1382-92. PubMed ID: 16625656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micronized drug powders in binary mixtures and the effect of physical properties on aerosolization from combination drug dry powder inhalers.
    Jetmalani K; Young PM; Smith T; Stewart P; Traini D
    Drug Dev Ind Pharm; 2012 Dec; 38(12):1504-11. PubMed ID: 22335558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers.
    Elhissi AM; Karnam KK; Danesh-Azari MR; Gill HS; Taylor KM
    J Pharm Pharmacol; 2006 Jul; 58(7):887-94. PubMed ID: 16805947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.
    Corrigan DO; Corrigan OI; Healy AM
    Int J Pharm; 2006 Sep; 322(1-2):22-30. PubMed ID: 16815654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach.
    Zhou QT; Qu L; Larson I; Stewart PJ; Morton DA
    Int J Pharm; 2010 Jul; 394(1-2):50-9. PubMed ID: 20435112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Powder specific active dispersion for generation of pharmaceutical aerosols.
    Crowder T; Hickey A
    Int J Pharm; 2006 Dec; 327(1-2):65-72. PubMed ID: 16930884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro.
    Srichana T; Martin GP; Marriott C
    Eur J Pharm Sci; 1998 Dec; 7(1):73-80. PubMed ID: 9845780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Aerosol Devices and Administration Techniques on Drug Delivery in a Simulated Spontaneously Breathing Pediatric Tracheostomy Model.
    Alhamad BR; Fink JB; Harwood RJ; Sheard MM; Ari A
    Respir Care; 2015 Jul; 60(7):1026-32. PubMed ID: 25737572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of carrier on the performance of dry powder inhalers.
    Saint-Lorant G; Leterme P; Gayot A; Flament MP
    Int J Pharm; 2007 Apr; 334(1-2):85-91. PubMed ID: 17113733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aerosolization behavior of carrier-free L-leucine coated salbutamol sulphate powders.
    Raula J; Lähde A; Kauppinen EI
    Int J Pharm; 2009 Jan; 365(1-2):18-25. PubMed ID: 18789380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.